The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment
The report titled “The US Pharmaceutical Market Outlook to 2015 - Evolving Opportunities in the Biologics Segment” provides a comprehensive analysis on the Pharmaceutical market in the US covering various aspects such as market size of the pharmaceutical industry, market segmentation by Branded and Generic drugs, and Prescribed and OTC drugs and Biologics and specialty drugs segments. The report also provides information on the government regulations, export and imports of pharmaceutical sand medicines. The report also entails competitive landscape and profiles of the major players operating in the industry. The future projections are included to provide an insight on the prospects in the US pharmaceutical industry.
The US Pharmaceutical market is the largest pharmaceutical market in the world which has registered a marginal slowdown in the growth rate over the period. The slowing growth rate can be attributed to an increasing number of drugs losing its patent security and surrogated by generic equivalents. In terms of sales value, the US pharmaceutical industry has recorded consistent growth at a 5 year CAGR of 3.2% over the period. The sales of Pharmaceuticals in the US grew from USD ~ billion in 2005 to USD ~ billion in 2010.
Branded drugs hold the major market share in the total pharmaceutical drugs sales in the US. In 2010, branded drugs accounted for ~ of the total drugs sold, but this market share decreased over the period from ~ in 2005. The sales of branded drugs grew from USD ~billion in 2005 to USD ~ billion in 2010 at a CAGR of ~. Generic drugs, which showcased a growth in the market share over the period from ~ share in 2005 to ~ in 2010 and posted sales of USD ~ billion, which has grown at a 5 year CAGR of 9.4% from sales worth of USD ~ billion in 2005.
The biopharmaceutical industry is one of the most research concentrated industries in the US. The expenditure on biopharmaceutical research and development has showcased a dependable growth over the period. The expenditure has grown from USD ~ billion in 2005 to USD ~ billion in 2010 at a CAGR of 5.4%. Avastin, Rituxan, Enbrel and Remicade among the world’s top selling biologics and each recorded sales above USD ~ billion in the US in 2010. Bristol-Myers Squibb is the largest company in the US in terms of biopharmaceutical drugs sales. The company held a market share of ~% and recorded sales of USD ~ billion. The US biologic drugs market is estimated to grow at a 5 year CAGR of 8.1% from 2011 to reach USD ~ billion by 2016.
The US pharmaceutical industry is expected to grow over the period at a CAGR of 4.8% with projected sales of USD ~ billion in 2015. It is estimated that the research and development productivity will increase and will trigger the growth in the market. Additionally the companies will focus on developing pharmaceutical drugs for personalized healthcare.
The US pharmaceutical industry witnessed revenues worth of USD ~ billion in 2011. Pfizer is the largest company with a market share of ~ and sales of USD ~ billion in 2011. Pfizer’s blockbuster drug, Lipitor played a major role in helping the company secure its number one position.
Key Topics Covered in the Report:
The US Pharmaceutical market is the largest pharmaceutical market in the world which has registered a marginal slowdown in the growth rate over the period. The slowing growth rate can be attributed to an increasing number of drugs losing its patent security and surrogated by generic equivalents. In terms of sales value, the US pharmaceutical industry has recorded consistent growth at a 5 year CAGR of 3.2% over the period. The sales of Pharmaceuticals in the US grew from USD ~ billion in 2005 to USD ~ billion in 2010.
Branded drugs hold the major market share in the total pharmaceutical drugs sales in the US. In 2010, branded drugs accounted for ~ of the total drugs sold, but this market share decreased over the period from ~ in 2005. The sales of branded drugs grew from USD ~billion in 2005 to USD ~ billion in 2010 at a CAGR of ~. Generic drugs, which showcased a growth in the market share over the period from ~ share in 2005 to ~ in 2010 and posted sales of USD ~ billion, which has grown at a 5 year CAGR of 9.4% from sales worth of USD ~ billion in 2005.
The biopharmaceutical industry is one of the most research concentrated industries in the US. The expenditure on biopharmaceutical research and development has showcased a dependable growth over the period. The expenditure has grown from USD ~ billion in 2005 to USD ~ billion in 2010 at a CAGR of 5.4%. Avastin, Rituxan, Enbrel and Remicade among the world’s top selling biologics and each recorded sales above USD ~ billion in the US in 2010. Bristol-Myers Squibb is the largest company in the US in terms of biopharmaceutical drugs sales. The company held a market share of ~% and recorded sales of USD ~ billion. The US biologic drugs market is estimated to grow at a 5 year CAGR of 8.1% from 2011 to reach USD ~ billion by 2016.
The US pharmaceutical industry is expected to grow over the period at a CAGR of 4.8% with projected sales of USD ~ billion in 2015. It is estimated that the research and development productivity will increase and will trigger the growth in the market. Additionally the companies will focus on developing pharmaceutical drugs for personalized healthcare.
The US pharmaceutical industry witnessed revenues worth of USD ~ billion in 2011. Pfizer is the largest company with a market share of ~ and sales of USD ~ billion in 2011. Pfizer’s blockbuster drug, Lipitor played a major role in helping the company secure its number one position.
Key Topics Covered in the Report:
- The market size of US pharmaceutical industry by revenue
- Market segmentation on the basis of branded and generic drugs, and prescribed and OTC drugs.
- Import and Exports of pharmaceuticals and medicines
- Market size, market segmentation competitive landscape and future outlook of the US biologic drugs market
- Government regulations pertaining to the industry.
- Trends and developments pertaining to the industry.
- Competitive Landscape and Profile of the major players
- Cause and Effect Relationship Analysis between industry factors and expected US pharmaceutical industry prospects
- Future outlook and projections of the sales of pharmaceutical drugs and its segments in the US till 2015.
- Macroeconomic and industry factors affecting the industry
1. THE US PHARMACEUTICAL INDUSTRY INTRODUCTION
2. THE US PHARMACEUTICAL MARKET SIZE, 2005-2010
3. TOP 50 PHARMACEUTICAL DRUGS IN THE US
4. THE US REGULATIONS PERTAINING TO THE PHARMACEUTICAL INDUSTRY
General Overview
Health Care Reform
Patent
5. THE US PHARMACY DISTRIBUTION AND REIMBURSEMENT SYSTEM
6. THE US PHARMACEUTICAL MARKET SEGMENTATION
6.1. By Generic and Branded Drugs, 2005-2010
6.1.1. Generic Drugs Competitive Landscape, 2011
6.2. By Prescribed and Over the Counter Drugs (OTC), 2005-2010
6.2.1. Prescribed Drugs Market Segmentation, 2006-2010
6.2.1.1. Top Therapeutic Classes in the US by Prescriptions Dispensed and Spending, 2006-2010
6.2.1.2. The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, 2005-2010
6.2.1.3. The US Prescription Drug Competitive Landscape, 2010
6.2.1.4. Top US Pharmacies by Total Prescription Revenues, 2011
6.2.2. OTC Drugs Market Segmentation, 2007-2010
6.3. The US Biologics/Biopharmaceutical Market
6.3.1. The US Biologics/Biopharmaceutical Market Size By Value, 2006-2011
6.3.2. Top Selling Biologic Drugs, 2010
6.3.3. Top US Biopharmaceutical Companies Market Share, 2011
6.3.4. Biologic Drugs Future Projections, 2012-2016
6.4. The US Specialty Drugs Market
7. THE US PHARMACEUTICAL INDUSTRY TRENDS AND DEVELOPMENTS
Rising Expenditure on Biopharmaceutical Research and Development
Expanding Generic Drug Market
Rising Prescription Drug Prices
Rise in Shortage of Drugs
Rising M&A Activities in the US Pharmaceutical Market
8. EXPORTS AND IMPORTS OF PHARMACETICALS AND MEDICINES IN THE US, 2005-2010
9. THE US PHARMACEUTICAL INDUSTRY COMPETITIVE LANDSCAPE, 2011
10. THE US PHARMACEUTICAL INDUSTRY FUTURE OUTLOOK AND PROJECTIONS, 2011-2015
10.1. Cause and Effect Relationship Between Industry Factors and the US Pharmaceutical Market Prospects
11. MAJOR PHARMACEUTICAL COMPANY PROFILES
11.1. Pfizer Inc.
Company Overview
Business Strategies
Financial Performance
11.2. Merck & Co.
Company Overview
Business Strategies
Financial Performance
11.3. Novartis
Company Overview
Business Strategies
Financial Performance
11.4. AstraZeneca
Company Overview
Business Strategies
Financial Performance
11.5. GlaxoSmithKline
Company Overview
Business Strategies
Financial Performance
12. MACRO ECONOMIC AND INDUSTRY INDICATORS: CURRENT AND PROJECTIONS
12.1. Population, 2005-2015
12.2. Inpatient Admissions & Outpatients Visits, 2005-2010
12.3. Number of People with Health Insurance
12.4. Prescription Drug Price index, 2005-2015
12.5. Personal Disposable Income
13. APPENDIX
13.1. Market Definition
13.2. Abbreviations
13.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
13.4. Disclaimer
2. THE US PHARMACEUTICAL MARKET SIZE, 2005-2010
3. TOP 50 PHARMACEUTICAL DRUGS IN THE US
4. THE US REGULATIONS PERTAINING TO THE PHARMACEUTICAL INDUSTRY
General Overview
Health Care Reform
Patent
5. THE US PHARMACY DISTRIBUTION AND REIMBURSEMENT SYSTEM
6. THE US PHARMACEUTICAL MARKET SEGMENTATION
6.1. By Generic and Branded Drugs, 2005-2010
6.1.1. Generic Drugs Competitive Landscape, 2011
6.2. By Prescribed and Over the Counter Drugs (OTC), 2005-2010
6.2.1. Prescribed Drugs Market Segmentation, 2006-2010
6.2.1.1. Top Therapeutic Classes in the US by Prescriptions Dispensed and Spending, 2006-2010
6.2.1.2. The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, 2005-2010
6.2.1.3. The US Prescription Drug Competitive Landscape, 2010
6.2.1.4. Top US Pharmacies by Total Prescription Revenues, 2011
6.2.2. OTC Drugs Market Segmentation, 2007-2010
6.3. The US Biologics/Biopharmaceutical Market
6.3.1. The US Biologics/Biopharmaceutical Market Size By Value, 2006-2011
6.3.2. Top Selling Biologic Drugs, 2010
6.3.3. Top US Biopharmaceutical Companies Market Share, 2011
6.3.4. Biologic Drugs Future Projections, 2012-2016
6.4. The US Specialty Drugs Market
7. THE US PHARMACEUTICAL INDUSTRY TRENDS AND DEVELOPMENTS
Rising Expenditure on Biopharmaceutical Research and Development
Expanding Generic Drug Market
Rising Prescription Drug Prices
Rise in Shortage of Drugs
Rising M&A Activities in the US Pharmaceutical Market
8. EXPORTS AND IMPORTS OF PHARMACETICALS AND MEDICINES IN THE US, 2005-2010
9. THE US PHARMACEUTICAL INDUSTRY COMPETITIVE LANDSCAPE, 2011
10. THE US PHARMACEUTICAL INDUSTRY FUTURE OUTLOOK AND PROJECTIONS, 2011-2015
10.1. Cause and Effect Relationship Between Industry Factors and the US Pharmaceutical Market Prospects
11. MAJOR PHARMACEUTICAL COMPANY PROFILES
11.1. Pfizer Inc.
Company Overview
Business Strategies
Financial Performance
11.2. Merck & Co.
Company Overview
Business Strategies
Financial Performance
11.3. Novartis
Company Overview
Business Strategies
Financial Performance
11.4. AstraZeneca
Company Overview
Business Strategies
Financial Performance
11.5. GlaxoSmithKline
Company Overview
Business Strategies
Financial Performance
12. MACRO ECONOMIC AND INDUSTRY INDICATORS: CURRENT AND PROJECTIONS
12.1. Population, 2005-2015
12.2. Inpatient Admissions & Outpatients Visits, 2005-2010
12.3. Number of People with Health Insurance
12.4. Prescription Drug Price index, 2005-2015
12.5. Personal Disposable Income
13. APPENDIX
13.1. Market Definition
13.2. Abbreviations
13.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
13.4. Disclaimer
LIST OF FIGURES
Figure 1: The US Pharmaceutical Market Size by Total Sales, in USD Billion, 2005-2010
Figure 2: The US Pharmacy Distribution and Reimbursement System
Figure 3: The US Pharmaceutical Market Segmentation by Branded and Generic Drugs on the Basis of Revenue, in Percentage, 2005-2010
Figure 4: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the Basis of Revenue, in Percentage, 2005-2010
Figure 5: The US Prescription Drug Competitive Landscape by Number of Prescriptions Percentage, Million, 2010
Figure 6: The US Biopharmaceuticals Market Size by Value in USD Billion, 2006-2011
Figure 7: Market Share of the Major Biopharmaceutical Companies in the US on the Basis of Revenue, Percentage, 2011
Figure 8: Future Projections of US Biologic Drug Sales, USD Billion, 2012-2016
Figure 9: Top Specialty Categories by Percent Contribution to Net Specialty Costs, 2010
Figure 10: The US Expenditure on Biopharmaceutical Research and Development, in USD Billion, 2005-2010
Figure 11: Average Drug Prices for All Prescription, Branded Drugs and Generic Drugs, USD, 2005-2010
Figure 12: Number of M&A Deals in the US Pharmaceutical Sector by Value, in Number, 2010
Figure 13: The US Pharmaceutical Industry Future Projections in Terms of Sales, in USD Billion, 2011-2015
Figure 14: The US Pharmaceutical Companies’ Market Share in Percentage, 2011
Figure 15: Pfizer Biopharmaceutical Sales in the US, in USD Billion, 2005-2011
Figure 16: Merck Pharmaceutical Drugs Sales in the US, in USD Billion, 2009-2011
Figure 17: Novartis Drug Revenue in the US, in USD Billion, 2005-2011
Figure 18: AstraZeneca Pharmaceutical Drug Sales, in USD Billion, 2005-2011
Figure 19: GlaxoSmithKline Pharmaceutical Drug Sales in the US, in USD Billion, 2007-2011
Figure 20: The US Population in Million, 2005-2015
Figure 21: Inpatient Admissions in Community Hospitals in the US, in Million, 2005-2010
Figure 22: Outpatient Visits in Community Hospitals in the US, in Million, 2005-2010
Figure 23: Total Number of People in the US with Health Insurance, in Million, 2005-2010
Figure 24: The US Prescription Drug Price Index, 2005-2015
Figure 25: Personal Disposable Income in the US, in USD Billion, 2005-2015
Figure 1: The US Pharmaceutical Market Size by Total Sales, in USD Billion, 2005-2010
Figure 2: The US Pharmacy Distribution and Reimbursement System
Figure 3: The US Pharmaceutical Market Segmentation by Branded and Generic Drugs on the Basis of Revenue, in Percentage, 2005-2010
Figure 4: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the Basis of Revenue, in Percentage, 2005-2010
Figure 5: The US Prescription Drug Competitive Landscape by Number of Prescriptions Percentage, Million, 2010
Figure 6: The US Biopharmaceuticals Market Size by Value in USD Billion, 2006-2011
Figure 7: Market Share of the Major Biopharmaceutical Companies in the US on the Basis of Revenue, Percentage, 2011
Figure 8: Future Projections of US Biologic Drug Sales, USD Billion, 2012-2016
Figure 9: Top Specialty Categories by Percent Contribution to Net Specialty Costs, 2010
Figure 10: The US Expenditure on Biopharmaceutical Research and Development, in USD Billion, 2005-2010
Figure 11: Average Drug Prices for All Prescription, Branded Drugs and Generic Drugs, USD, 2005-2010
Figure 12: Number of M&A Deals in the US Pharmaceutical Sector by Value, in Number, 2010
Figure 13: The US Pharmaceutical Industry Future Projections in Terms of Sales, in USD Billion, 2011-2015
Figure 14: The US Pharmaceutical Companies’ Market Share in Percentage, 2011
Figure 15: Pfizer Biopharmaceutical Sales in the US, in USD Billion, 2005-2011
Figure 16: Merck Pharmaceutical Drugs Sales in the US, in USD Billion, 2009-2011
Figure 17: Novartis Drug Revenue in the US, in USD Billion, 2005-2011
Figure 18: AstraZeneca Pharmaceutical Drug Sales, in USD Billion, 2005-2011
Figure 19: GlaxoSmithKline Pharmaceutical Drug Sales in the US, in USD Billion, 2007-2011
Figure 20: The US Population in Million, 2005-2015
Figure 21: Inpatient Admissions in Community Hospitals in the US, in Million, 2005-2010
Figure 22: Outpatient Visits in Community Hospitals in the US, in Million, 2005-2010
Figure 23: Total Number of People in the US with Health Insurance, in Million, 2005-2010
Figure 24: The US Prescription Drug Price Index, 2005-2015
Figure 25: Personal Disposable Income in the US, in USD Billion, 2005-2015
LIST OF TABLES
Table 1: Sales of the Top 50 Drugs in the US, in USD million, 2005-2010
Table 2: Sales of the Top 50 Drugs in the US in Million Units, 2005-2010
Table 3: Major Provisions/ Amendments in the ACA and their Impacts
Table 4: The US Pharmaceuticals Market Segmentation by Branded and Generic Drugs on the Basis of Revenue, in USD Billion, 2005-2010
Table 5: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the Basis of Revenue, in USD Billion, 2005-2010
Table 6: Top 10 Prescribed Drugs in the US by Dispensed Prescriptions, in Million, 2006-2010
Table 7: Top 10 Therapeutic Classes in the US by Dispensed Prescriptions, in Million, 2006-2010
Table 8: Top 10 Therapeutic Classes in the US by Spending, in USD Billion, 2006-2010
Table 9: The US Retail Prescription Drug Sales Segmentation in Volume by Number of Prescriptions in Type of Sales Outlet, Million, 2005-2010
Table 10: The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, USD Billion, 2005-2010
Table 11: Top US Companies’ by Number of Prescriptions Dispensed, Million, 2010
Table 12: Top US Pharmacies by Estimated Total Prescription Revenues, USD Billion, 2011
Table 13: OTC Drugs Segmentations by Medicine Category, USD Million, 2007-2010
Table 14: The US Sales of Top Selling Global Biologic Drugs, USD billion, 2010
Table 15: Top US Companies’ by Sales of Biopharmaceutical Drugs, USD Billion, 2011
Table 16: Specialty Categories, Average Cost in USD and Relative Available Medications, 2010
Table 17: Top Pharmaceutical Drugs Losing Patent Protection in 2011 and 2012
Table 18: The US Pharmaceuticals and Medicines Exports, USD Million, 2005-2010
Table 19: The US Pharmaceuticals and Medicines Imports, USD Million, 2005-2010
Table 20: US Pharmaceutical Companies’ Sales USD Billion, 2011
Table 21: The US Pharmaceutical Industry Future Projections in Terms of Sales by Prescribed and OTC drugs, and Branded and Generic Drugs, USD Billion, 2011-2015
Table 22: Cause and Effect Relationship between Industry Factors and the US Pharmaceuticals Industry Prospects
Table 23: Pfizer’s Product Patent Expiration Year
Table 24: Top Selling Pfizer’s Biopharmaceutical Products in the US in USD Million, and their Revenue Contribution in Percentage, 2011
Table 25: Merck’s Top Pharmaceutical Drug Sales in US, USD Million, 2010-2011
Table 26: Novartis’ Revenue Segmentation by Pharmaceutical and Sandoz Division in the US, USD Billion, 2005 - 2011
Table 27: Novartis’ Top Pharmaceutical Drug Sales in the US, USD Million, 2011
Table 28: Astra Zeneca’s pharmaceutical drug sales in the US by product and Therapeutic category, in USD Million, 2011
Table 29: GlaxoSmithKline’s Top Selling Pharmaceutical Drugs in the US, in USD Million, 2011
Table 30: Demographic Distribution of Population in US on the basis of Age, in Million, 2009-2012
Table 31: Correlation Matrix of the US Pharmaceutical Market
Table 32: Regression Coefficients Output
Table 1: Sales of the Top 50 Drugs in the US, in USD million, 2005-2010
Table 2: Sales of the Top 50 Drugs in the US in Million Units, 2005-2010
Table 3: Major Provisions/ Amendments in the ACA and their Impacts
Table 4: The US Pharmaceuticals Market Segmentation by Branded and Generic Drugs on the Basis of Revenue, in USD Billion, 2005-2010
Table 5: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the Basis of Revenue, in USD Billion, 2005-2010
Table 6: Top 10 Prescribed Drugs in the US by Dispensed Prescriptions, in Million, 2006-2010
Table 7: Top 10 Therapeutic Classes in the US by Dispensed Prescriptions, in Million, 2006-2010
Table 8: Top 10 Therapeutic Classes in the US by Spending, in USD Billion, 2006-2010
Table 9: The US Retail Prescription Drug Sales Segmentation in Volume by Number of Prescriptions in Type of Sales Outlet, Million, 2005-2010
Table 10: The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, USD Billion, 2005-2010
Table 11: Top US Companies’ by Number of Prescriptions Dispensed, Million, 2010
Table 12: Top US Pharmacies by Estimated Total Prescription Revenues, USD Billion, 2011
Table 13: OTC Drugs Segmentations by Medicine Category, USD Million, 2007-2010
Table 14: The US Sales of Top Selling Global Biologic Drugs, USD billion, 2010
Table 15: Top US Companies’ by Sales of Biopharmaceutical Drugs, USD Billion, 2011
Table 16: Specialty Categories, Average Cost in USD and Relative Available Medications, 2010
Table 17: Top Pharmaceutical Drugs Losing Patent Protection in 2011 and 2012
Table 18: The US Pharmaceuticals and Medicines Exports, USD Million, 2005-2010
Table 19: The US Pharmaceuticals and Medicines Imports, USD Million, 2005-2010
Table 20: US Pharmaceutical Companies’ Sales USD Billion, 2011
Table 21: The US Pharmaceutical Industry Future Projections in Terms of Sales by Prescribed and OTC drugs, and Branded and Generic Drugs, USD Billion, 2011-2015
Table 22: Cause and Effect Relationship between Industry Factors and the US Pharmaceuticals Industry Prospects
Table 23: Pfizer’s Product Patent Expiration Year
Table 24: Top Selling Pfizer’s Biopharmaceutical Products in the US in USD Million, and their Revenue Contribution in Percentage, 2011
Table 25: Merck’s Top Pharmaceutical Drug Sales in US, USD Million, 2010-2011
Table 26: Novartis’ Revenue Segmentation by Pharmaceutical and Sandoz Division in the US, USD Billion, 2005 - 2011
Table 27: Novartis’ Top Pharmaceutical Drug Sales in the US, USD Million, 2011
Table 28: Astra Zeneca’s pharmaceutical drug sales in the US by product and Therapeutic category, in USD Million, 2011
Table 29: GlaxoSmithKline’s Top Selling Pharmaceutical Drugs in the US, in USD Million, 2011
Table 30: Demographic Distribution of Population in US on the basis of Age, in Million, 2009-2012
Table 31: Correlation Matrix of the US Pharmaceutical Market
Table 32: Regression Coefficients Output
